SABCS 2019 Conference Review, reviewed by A/Prof Andy Redfern

In this review:

Tucatinib for pre-treated HER2+ metastatic breast cancer
Trastuzumab-drug conjugate for pre-treated HER2+ metastatic breast cancer
Adjuvant chemotherapy-trastuzumabpertuzumab for HER2+ early breast cancer
Meta-analysis of capecitabine as neo-/adjuvant chemotherapy for early breast cancer
Durvalumab vs chemotherapy as maintenance treatment for metastatic breast cancer
Neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab for early TNBC
Role of ctDNA testing in directing targeted therapies for advanced breast cancer
Costs and effects of MRI vs mammography for screening women with familial risk
Oral vs IV paclitaxel in women with metastatic breast cancer
Cisplatin vs AC as neoadjuvant treatment in germline BRCA-mutated HER2- patients

Please login below to download this issue (PDF)